Strategic Timing of AntiRetroviral Treatment(START) - START

niversidad de Minnesota - EEUU,0 个研究点目标入组 216 人开始时间: 2009年7月3日最近更新: 2023年9月4日

试验速览

暂无简介。

•Signature of informed consent
•Documented HIV infection by HIV-RNA plasma viral load, rapid HIV test or any approved ELISA test ´´; and confirmed by a different method such as rapid HIV test, Western Blot, HIV culture, HIV antigen, or HIV pro-viral DNA at any time prior to entering the study.
•Age> 18 years
•Karnofsky score> 80 (indicator that the participant can carry out normal activities)
•Perceived life expectancy of at least 6 months
•For women of childbearing age, willingness to use contraceptives as described in the product information of prescription ART medications.
•2 CD4 + cell counts> 500 consecutive cells / mm3, separated by at least two weeks within 60 days prior to randomization.

•History of the use of antiretroviral treatment (ART) or lL-2.
•Diagnosis of any defining clinical event of AIDS prior to randomization (esophageal candidiasis and chronic Herpes simplex infection are included)
•Evidence of progression of HIV disease such as oral thrush, weight loss or fever of no clear cause.
•Cardiovascular event (myocardial infarction, angioplasty, coronary bypass graft, stroke) within 6 months prior to randomization
•Non-defining AIDS cancer, basal cell and squamous cell carcinomas are excluded, within 6 months prior to randomization.
•Dialysis within 6 months prior to randomization *
•History of decompensated liver disease
•Current mandatory confinement or detention (Involuntary imprisonment) for the treatment of a psychiatric or physical illness
•Pregnancy or current lactation (a negative serum or urine pregnancy test is required, within 14 days prior to randomization for women with fertile potential)

发起方

niversidad de Minnesota - EEUU,